Immunovant
IMVT · NASDAQ
Bulios Fair Price
$31.3
6.5% downside
Trenutna cena
$33.49
Po podatkih Bulios Fair Price je delnica IMVT trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Immunovant, Inc. is an American biotechnology company focused on the development of innovative immunotherapies for the treatment of autoimmune diseases. The company specializes in the development of monoclonal antibodies that target specific immune pathways, which can help patients suffering from conditions such as myasthenia gravis, autoimmune hemolytic anemia, and others. Immunovant aims to provide effective therapeutic options for patients whose current treatments are insufficient or associated with undesirable side effects.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Eric Venker
Employees
315
Headquarters
Durham
Prihajajoči dogodki
Earnings
Upcoming earnings report